![Stacie Dusetzina, PhD, and Katherine Reeder-Hayes, MD, MBA, were co-principal investigators of the study.](https://unclineberger.org/wp-content/uploads/sites/867/2018/10/her2-treatment-image2-600x400.jpeg)
April 12, 2016
Older women, especially blacks, receive targeted breast cancer treatment at low rates
Katherine Reeder-Hayes, MD, MBA, and her colleagues report that women age 66 and older who have HER2-positive breast cancer were less likely than younger women to be treated with trastuzumab (Herceptin), a proven, yet expensive, drug therapy.